Just when I thought the trend of short, fast, illuminated rifle scopes was cooling, a new class of excellent low-power variable optics revived my affection for these do-everything scopes. The new ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Although news of Scorpion’s return came from legitimate news outlets, Michael Mando’s role was ...

The cover of "The Hundred Years' Trial" and author Harold Gouzoules (top) and Alexander Gouzoules (bottom). (Courtesy of Johns Hopkins University Press, Emory University and Samantha Xia) One hundred ...

DAYTON, TN – Inside a sweltering courtroom in July, a fierce debate was underway here in this small Tennessee town. Modern science versus religion and the battle over what is taught inside America’s ...

One hundred years ago, on July 10, 1925, the trial of John T. Scopes began. It concluded 11 days later with a conviction. Today, this battle in the conflict over religion and science in United States ...

Why is Christian Science in our name? Our name is about honesty. The Monitor is owned by The First Church of Christ, Scientist, and we’ve always been transparent about that. The church publishes the ...

The Pirelli Scorpion XTM AT is the most rugged offering from the Italian tire maker, and we put it to work in the unforgiving terrain of the Mojave Desert. Pirelli positions the Scorpion XTM as the ...

In 1925, a small-town trial became a national spectacle, pitting faith against science. Here's what to know about the lasting legacy of the Scopes 'Monkey' Trial. Jock the monkey listens in on the ...

A venomous creature from the Amazon rainforest may hold the key to fighting one of the deadliest cancers affecting women today. According to the American Cancer Society, skin cancers aside, breast ...

One hundred years ago, a small town in eastern Tennessee captured the attention of the entire country. A biology teacher in Dayton was accused of teaching human evolution to his students — which was ...

After Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the biotech is selling off its other two clinical assets and spinning out a new company to advance its three ...